CRBP News and Press, Corbus Pharmaceuticals Holdings Inc. From 10/03/23

NORWOOD, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that it will host a Virtual ‘Meet the Expert’ event on the development of a next generation Nectin-4 anti...

Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting PR Newswire NORWOOD, Mass. , Sept. 27, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or...

Corbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics PR Newswire NORWOOD, Mass. , Sept. 19, 2023 /PRNewswire/ -- Corbus Phar...

2023-08-08 09:02:34 ET Corbus Pharmaceuticals press release ( NASDAQ: CRBP ): Q2 GAAP EPS of -$2.05. As of June 30, 2023, the company has $36.6 million of cash, cash equivalents and investments on hand which is expected to fund operations through the second quarter of 20...

Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update PR Newswire CRB-701 Phase 1 trial in China is ahead of schedule with dose escalation completion expected Q4 2023 and U.S. clinical trial start planned for Q1 2024 P...

2023-08-04 13:07:47 ET Summary Corbus Pharmaceuticals is shifting its strategy after the Lenabasum failure, focusing on new drugs CRB-601 & CRB-701. Despite a healthy balance sheet, Corbus' cash reserves are steadily depleting, especially when the company has generated no reve...

Corbus Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference PR Newswire NORWOOD, Mass. , July 31, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today an...

2023-06-26 10:23:21 ET Corbus Pharmaceuticals Holdings ( NASDAQ: CRBP ) has joined Russell Microcap Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens today. CRBP is -10.1% to $7.9 Source: Press Release ...

Corbus Pharmaceuticals Set to Join Russell Microcap® Index PR Newswire NORWOOD, Mass. , June 26, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that the Com...

2023-05-31 10:05:20 ET Gainers: Marker Therapeutics ( MRKR ) +34% . Nano-X Imaging ( NNOX ) +13% . Zai Lab ( ZLAB ) +9% . Invivyd ( IVVD ) +8% . Corbus Pharmaceuticals ( CRBP ) +7% . Losers: Belite Bio ( BLTE ) ...